DK3247352T3 - Cebranopadol til behandling af smerter hos individer med forringet lever- og/eller forringet nyrefunktion - Google Patents
Cebranopadol til behandling af smerter hos individer med forringet lever- og/eller forringet nyrefunktion Download PDFInfo
- Publication number
- DK3247352T3 DK3247352T3 DK16701414.1T DK16701414T DK3247352T3 DK 3247352 T3 DK3247352 T3 DK 3247352T3 DK 16701414 T DK16701414 T DK 16701414T DK 3247352 T3 DK3247352 T3 DK 3247352T3
- Authority
- DK
- Denmark
- Prior art keywords
- cebranopadol
- individuals
- pain
- deteriorated
- treatment
- Prior art date
Links
- CSMVOZKEWSOFER-RQNOJGIXSA-N cebranopadol Chemical compound C1([C@]2(CC[C@@]3(CC2)C2=C(C4=CC(F)=CC=C4N2)CCO3)N(C)C)=CC=CC=C1 CSMVOZKEWSOFER-RQNOJGIXSA-N 0.000 title 1
- 229950004621 cebranopadol Drugs 0.000 title 1
- 230000003907 kidney function Effects 0.000 title 1
- 210000004185 liver Anatomy 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Addiction (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562106845P | 2015-01-23 | 2015-01-23 | |
| PCT/EP2016/000114 WO2016116280A1 (en) | 2015-01-23 | 2016-01-22 | Cebranopadol for treating pain in subjects with impaired hepatic and/or impaired renal function |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3247352T3 true DK3247352T3 (da) | 2020-09-07 |
Family
ID=55229644
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16701414.1T DK3247352T3 (da) | 2015-01-23 | 2016-01-22 | Cebranopadol til behandling af smerter hos individer med forringet lever- og/eller forringet nyrefunktion |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10022353B2 (da) |
| EP (2) | EP3735970B1 (da) |
| JP (2) | JP6673924B2 (da) |
| CN (1) | CN107427493A (da) |
| AU (1) | AU2016208779B2 (da) |
| CA (1) | CA2974578C (da) |
| DK (1) | DK3247352T3 (da) |
| EA (1) | EA201791662A1 (da) |
| IL (1) | IL253268A0 (da) |
| MX (1) | MX2017009416A (da) |
| TW (1) | TW201642853A (da) |
| WO (1) | WO2016116280A1 (da) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12168004B2 (en) | 2014-02-05 | 2024-12-17 | Merck Sharp & Dohme Llc | Treatment of migraine |
| KR102448369B1 (ko) | 2014-02-05 | 2022-09-28 | 머크 샤프 앤드 돔 엘엘씨 | Cgrp-활성 화합물에 대한 정제 제제 |
| CN107427493A (zh) * | 2015-01-23 | 2017-12-01 | 格吕伦塔尔有限公司 | 用于治疗肝功能受损和/或肾功能受损的受试者的疼痛的Cebranopadol |
| WO2017148595A1 (en) | 2016-02-29 | 2017-09-08 | Grünenthal GmbH | Titration of cebranopadol |
| IT201700057899A1 (it) | 2017-05-29 | 2018-11-29 | Univ Degli Studi Di Camerino | Co-attivatori dei recettori MOP e NOP nel trattamento della dipendenza da droghe e/o psicostimolanti |
| US12090148B2 (en) | 2020-07-29 | 2024-09-17 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| US12383545B1 (en) | 2018-06-08 | 2025-08-12 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| MX2023007575A (es) | 2020-12-22 | 2023-09-21 | Allergan Pharmaceuticals Int Ltd | Tratamiento de la migraña. |
| AU2022353124A1 (en) | 2021-09-27 | 2024-04-11 | Allergan Pharmaceuticals International Limited | Combination comprising atogepant for treating migraine |
| WO2024129782A1 (en) | 2022-12-12 | 2024-06-20 | Park Therapeutics, Inc. | Regimens and compositions useful for alleviating pain |
| EP4665333A1 (en) | 2023-02-15 | 2025-12-24 | Adneuris Therapeutics, Inc. | Regimens and compositions useful for alleviating pain |
| WO2026035694A1 (en) | 2024-08-05 | 2026-02-12 | Adneuris Therapeutics, Inc. | Cebranopadol useful for preventing or reducing opioid induced respiratory depression |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10252667A1 (de) * | 2002-11-11 | 2004-05-27 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
| DE102005016460A1 (de) | 2005-04-11 | 2006-10-19 | Grünenthal GmbH | Spriocyclische Cyclohexanderivate zur Behandlung von Substanzabhängigkeit |
| DE102006046745A1 (de) | 2006-09-29 | 2008-04-03 | Grünenthal GmbH | Gemischte ORL1/µ-Agonisten zur Behandlung von Schmerz |
| DE102007009319A1 (de) * | 2007-02-22 | 2008-08-28 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
| JP5792300B2 (ja) | 2010-08-04 | 2015-10-07 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | ６’−フルオロ−（Ｎ−メチル−又はＮ，Ｎ−ジメチル−）−４−フェニル−４’，９’−ジヒドロ−３’Ｈ−スピロ［シクロヘキサン−１，１’−ピラノ［３，４，ｂ］インドール］−４−アミンを含む医薬剤形 |
| DK2600846T3 (da) | 2010-08-04 | 2016-01-11 | Gruenenthal Gmbh | Farmaceutisk doseringsform omfattende 6'-fluoro-(n-methyl- eller n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexan-1,1'-pyrano[3,4,b]indol]-4-amin |
| CN103153282B (zh) | 2010-08-04 | 2015-08-19 | 格吕伦塔尔有限公司 | 含6’-氟-(n-甲基-或n,n-二甲基-)-4-苯基-4’,9’-二氢-3’h-螺[环己烷-1,1’-吡喃并[3,4,b]吲哚]-4-胺的药物剂型 |
| TR201808244T4 (tr) * | 2010-08-04 | 2018-07-23 | Gruenenthal Gmbh | Nöropatik ağrının tedavisi için 6'-floro-(n-metil- veya n,n-dimetil-)-4-fenil-4',9'-dihidro-3'h-spiro[siklohekzan-1,1'-pirano[3,4,b]indol]-4-amin içeren farmasötik dozaj formu. |
| CA2841032C (en) * | 2011-07-08 | 2020-12-15 | Grunenthal Gmbh | Crystalline (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine |
| ES2589259T3 (es) | 2011-12-12 | 2016-11-11 | Grünenthal GmbH | Formas sólidas de (1R,4R)-6'-fluor-(N,N-dimetil)-4-fenil-4',9'-dihidro-3'H-espiro-[ciclohexano-1,1'-pirano[3,4,b]indol]-4-amina y ácido sulfúrico |
| PL2809307T3 (pl) | 2012-01-31 | 2018-06-29 | Grünenthal GmbH | Plaster farmaceutyczny do podawania przezskórnego (1r,4r)-6'-fluoro-N,N-dimetylo-4-fenylo-4',9'-dihydro-3'H-spiro[cykloheksano-1,1'-pirano[3,4-b]indolo]-4-aminy |
| WO2013113857A1 (en) | 2012-02-03 | 2013-08-08 | Grünenthal GmbH | (1r,4r)-6'-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4',9'-dihydro-3'h-spiro-[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine for treating fibromyalgia and chronic fatigue syndrome |
| US9345689B2 (en) | 2012-05-18 | 2016-05-24 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N, N-dimethyl-4-phenyl-4,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and an anticonvulsant |
| US8912226B2 (en) | 2012-05-18 | 2014-12-16 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1r,4r) -6′-fluoro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a NSAR |
| US20130310435A1 (en) | 2012-05-18 | 2013-11-21 | Gruenenthal Gmbh | Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N, N-dimethyl-4-phenyl-4,9' -dihydro-3'H-spiro[cyclohexane-1,1' -pyrano[3,4,b]indol]-4-amine and Paracetamol or Propacetamol |
| US9308196B2 (en) | 2012-05-18 | 2016-04-12 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1 r,4r) -6'-fluoro-N ,N-dimethyl-4-phenyl-4',9'-d ihydro-3'H-spiro[cyclohexane-1,1'-pyrano-[3,4,b]indol]-4-amine and an oxicam |
| US9320725B2 (en) | 2012-05-18 | 2016-04-26 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a gabapentinoid |
| US20130310385A1 (en) | 2012-05-18 | 2013-11-21 | Gruenenthal Gmbh | Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and Antidepressants |
| US9320729B2 (en) | 2012-05-18 | 2016-04-26 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1r,4r)-6′-flouro-N,N-dimethyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative |
| US9855286B2 (en) | 2012-05-18 | 2018-01-02 | Gruenenthal Gmbh | Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-di methyl-4-phenyl-4′,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano-[3,4,b]indol]-4-amine and a salicylic acid component |
| CN107427493A (zh) * | 2015-01-23 | 2017-12-01 | 格吕伦塔尔有限公司 | 用于治疗肝功能受损和/或肾功能受损的受试者的疼痛的Cebranopadol |
-
2016
- 2016-01-22 CN CN201680006851.4A patent/CN107427493A/zh active Pending
- 2016-01-22 AU AU2016208779A patent/AU2016208779B2/en not_active Expired - Fee Related
- 2016-01-22 WO PCT/EP2016/000114 patent/WO2016116280A1/en not_active Ceased
- 2016-01-22 EP EP20178446.9A patent/EP3735970B1/en active Active
- 2016-01-22 CA CA2974578A patent/CA2974578C/en active Active
- 2016-01-22 MX MX2017009416A patent/MX2017009416A/es unknown
- 2016-01-22 TW TW105101958A patent/TW201642853A/zh unknown
- 2016-01-22 EP EP16701414.1A patent/EP3247352B1/en active Active
- 2016-01-22 JP JP2017538612A patent/JP6673924B2/ja active Active
- 2016-01-22 DK DK16701414.1T patent/DK3247352T3/da active
- 2016-01-22 EA EA201791662A patent/EA201791662A1/ru unknown
- 2016-01-22 US US15/545,553 patent/US10022353B2/en active Active
-
2017
- 2017-07-02 IL IL253268A patent/IL253268A0/en unknown
-
2020
- 2020-03-04 JP JP2020036768A patent/JP7138300B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN107427493A (zh) | 2017-12-01 |
| MX2017009416A (es) | 2017-10-12 |
| US10022353B2 (en) | 2018-07-17 |
| AU2016208779B2 (en) | 2020-11-12 |
| AU2016208779A1 (en) | 2017-09-07 |
| EA201791662A1 (ru) | 2017-12-29 |
| JP7138300B2 (ja) | 2022-09-16 |
| EP3735970C0 (en) | 2023-08-09 |
| WO2016116280A1 (en) | 2016-07-28 |
| US20180008576A1 (en) | 2018-01-11 |
| JP2018502884A (ja) | 2018-02-01 |
| CA2974578C (en) | 2020-11-17 |
| CA2974578A1 (en) | 2016-07-28 |
| EP3247352B1 (en) | 2020-06-24 |
| JP6673924B2 (ja) | 2020-03-25 |
| JP2020105202A (ja) | 2020-07-09 |
| TW201642853A (zh) | 2016-12-16 |
| EP3735970B1 (en) | 2023-08-09 |
| EP3247352A1 (en) | 2017-11-29 |
| IL253268A0 (en) | 2017-08-31 |
| EP3735970A1 (en) | 2020-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3247352T3 (da) | Cebranopadol til behandling af smerter hos individer med forringet lever- og/eller forringet nyrefunktion | |
| BR112017024899A2 (pt) | proteínas de ligação trispecíficas e métodos de uso. | |
| DK3481846T3 (da) | 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande | |
| DK3500299T3 (da) | Kombination af zanubrutinib med et anti-CD20- eller et anti-PD-1-antistof til anvendelse i behandling af cancer | |
| DK3096798T3 (da) | Plasmakallikreinbindende proteiner og anvendelser deraf til behandling af hereditært angioødem | |
| SI3877376T1 (sl) | Spojine piridazinona in njihove uporabe | |
| DK3882250T3 (da) | Tetrahydropyranyl-amino-pyrrolopyrimidinon til anvendelse i behandling af btk-medierede forstyrrelser | |
| DK3197472T3 (da) | Rekombinante phe-frie proteiner til anvendelse i behandlingen af phenylketonuri | |
| DK3149019T3 (da) | Cholan-derivater til anvendelse ved behandling og/eller forebyggelse af FXR- og TGR5/GPBAR1-formidlede sygdomme | |
| DK3325488T3 (da) | Chiral diaryl-makrocyklus og anvendelse deraf til behandling af cancer | |
| EP3352781A4 (en) | 4 'SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS AND PREPARATIONS THEREOF | |
| DK3242947T3 (da) | Genterapi og elektroporese til behandling af maligniteter | |
| DK2945642T3 (da) | Faktor 1 protein til anvendelse i behandling eller forebyggelse af sygdomme | |
| DK3331879T3 (da) | Benzazolforbindelser og fremgangsmåder til fremstilling og anvendelse af forbindelserne | |
| DK3395359T3 (da) | Plasminogen til anvendelse til forebyggelse eller behandling af akut trombose og kronisk trombose | |
| DK3439663T3 (da) | Fremgangsmåder til behandling af pædiatriske cancere | |
| DK3710000T3 (da) | Tradipitant til anvendelse til behandling af gastroparese | |
| DK3273995T3 (da) | Kombineret anvendelse af alginatoligomerer og cftr-modulatoren lumacaftor i behandlingen af tilstande associeret med cftr-dysfunktion | |
| DK3391902T3 (da) | Plasminogen til anvendelse i behandlingen af diabetisk angiokardiopati | |
| DK3236960T3 (da) | Fluralaner til anvendelse i behandling af demodicose | |
| DK3174559T3 (da) | Radiomærkede antistoffragmenter til anvendelse inden for forebyggelsen og/eller behandlingen af cancer | |
| DK3259515T3 (da) | Fitting med coating, rørledningssystem og anvendelse af fittingen eller rørledningssystemet | |
| DK3532067T3 (da) | Liposomal formulering til anvendelse til behandling af cancer | |
| DK3200748T3 (da) | Sammensætninger og fremgangsmåder til behandling og profylakse af infektioner på operationssted | |
| DK3556383T3 (da) | Plasminogen til anvendelse ved behandling af diabetes |